September 30, 2011 – Cambridge Heart Inc. announced its HearTwave II System was cleared for sale by the Mexican regulatory authorities. In August 2010, the company executed an exclusive distribution agreement with Mayerick S.A. de S.V. to distribute the system, including the company’s microvolt t-wave alternans (MTWA) software and micro-V alternans sensors. This addition represents the company’s first distribution agreement in Latin America.
Sudden cardiac arrest (SCA) is the leading cause of death in the United States, accounting for approximately 300,000 deaths annually - more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8 percent, making prediction and prevention critically important.
There are an estimated 10 to 12 million heart attack and heart failure patients in the United States who can benefit from annual MTWA testing. Microvolt T-Wave Alternans is a marker of SCA risk that is measured during a non-invasive treadmill test.
For more information: www.cambridgeheart.com
June 16, 2026 
